PCSK9 Forum
20th March 2015
Facebook Twitter RSS YouTube
For latest updates
Register today
Home  |  About  |  PCSK9  |  News  |  Commentary  |  Trials  |  Videos  |  Resources  |  Contact
ACC 2015

Hot news on PCSK9 from the
American College of Cardiology 2015

ACC 2015 Do the evolocumab 2-weekly and monthly regimens provide equivalent LDL-C lowering?

One of the questions clinicians often raise if whether the two dose regimens for evolocumab produce similar low-density lipoprotein (LDL) cholesterol lowering. This study answers this question showing clinical equivalence for changes in lipid parameters, including low-density lipoprotein (LDL) cholesterol, apolipoprotein B and lipoprotein(a).…

Read the report here »

ACC 2015 Evolocumab effective in elderly patients; no safety issues

Treatment with the PCSK9 inhibitor evolocumab was effective in elderly patients (65 years and 75 years) with a side effect profile similar to placebo, according to the results of pooled analysis of nearly 2,000 patients from Phase 2, 3 and open-label studies…

Read the report here »

ACC 2015 ODYSSEY CHOICE: Flexibility in alirocumab dosing

Results from the ODYSSEY CHOICE studies indicate flexibility in dosing with alirocumab, with 4-weekly regimens shown to be effective and well tolerated, according to Dr Michel Farnier, Point Medical, Dijon, France. Many patients at moderate to high cardiovascular (CV) risk and with poorly controlled hypercholesterolaemia…

Read the report here »

ACC 2015: CASCADE FH: Unmet needs in education and care of familial hypercholesterolaemia

Baseline data from the CASCADE-FH Registry, presented at ACC 2015, highlight gaps in the care of patients with inherited high cholesterol - familial hypercholesterolaemia (FH). Only about 50% of patients understood the risks of their condition…

Read the report here »

ACC 2015: What do the OSLER and ODYSSEY data really show? Expert analysis from Professor Derick Raal

March 15, 2015 At an eagerly anticipated hotline at ACC 2015, a pre-specified, exploratory analysis of the OSLER studies, showed that the PCSK9 monoclonal antibody evolocumab reduced low-density lipoprotein (LDL) cholesterol by 61%, and that this was associated with a 53% reduction in cardiovascular events…

Read the report here »

Send an invitation to join PCSK9 Forum to your colleagues »
PCSK9 Education and Research Forum

Invotation from John Chapman
Aims & Objectives video
Read our Mission Statement
Partnership and outreach
Meet our Editorial Board
View Forthcoming Meetings
  Follow us on Twitter
For the latest from the 83rd Congress of the European Atherosclerosis Society
22-25 March 2015, UK
Latest Videos

Familial hypercholesterolaemia: putting the patient first
Katherine Wilemon

Weighing the cost versus benefit of PCSK9-targeted therapy
Lluis Masana

Loss of function mutations in PCSK9: the trigger for therapeutic development
Anne Tybjaerg-Hansen

View our YouTube channel »

Next week
Watch out for news from European Association of Atherosclerosis
22-25 March 2015, Glasgow, UK
  Supported by educational grants from: Amgen Lilly pFizer Sanofi  
Copyright PCSK9 Forum 2015. Please click here to unsubscribe from future mailings.